Sam Fazeli

Welcome to another episode of Bloomberg Intelligence, Vanguards of Healthcare podcast, where we speak with the leaders at the forefront of change in the healthcare industry.

My name is Sam Fazelli, and I'm a senior pharmaceuticals analyst at Bloomberg Intelligence, the in-house research arm of Bloomberg.

I'm thrilled to welcome Dr. Xingli Wang, co-president of Fosun Pharma, the parent company of Henleus.

He also serves as CEO of the Global R&D Center of Fosun Pharma, where he leads programs spanning from early development right up to

a late stage development for NDA submissions.

Dr. Wang is a physician with a strong academic background in China, Australia, and the US.

So I wanted to just give you everybody, our listeners, a little data set for the companies that Xing Li is involved in.

So Fosun Pharma has been independently listed in the Hong Kong Stock Exchange since 2013.

Market cap currently is around $10 billion.

revenues of around $5.7 billion in 2024.

And performance has been very strong, 70% in the past 12 months in terms of share price.

The company also has a meaningful shareholding in Henleus, which has been listed on HK index, Hong Kong index since 2019.

Market cap just shy of $5 billion and 2024 revenues of $795 million.

Now,

Helios has significantly outperformed the HS Bio, the Hong Kong Hang Seng Bio Index, and is up 300% in the past 12 months versus the 70% for the index itself, which is quite a wonderful thing to see.

We will get to talk a little bit about the performance of the China biotech sector.

But without further ado, I want to welcome Xing Li to the podcast.

And maybe if I could ask you to just tell us a little bit about your own history.

What's your background?

What brought you to sit in the seat that I see you sitting in right now?